

## Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With Anti-PD-1/Anti-PD-L1 Immunotherapy in a Community Oncology Setting

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

#### Inclusion Criteria:

- self-identify as African/African American/black (AA), or European American/ Caucasian/white (EA), or Hispanic/Latino ethnicity in combination with an AA or EA racial identity - current diagnosis of invasive cancer at stage I-IV - scheduled to receive anti-PD-1/-L1 ICI-containing therapy as standard of care treatment alone or in combination with co-treatments

---

#### Exclusion Criteria:

- identify as Asian, Pacific Islander, or American Indian/Alaskan Native - diagnosed with melanoma (because melanoma is very rare in AAs) - received prior immunotherapy for cancer,

### Conditions & Interventions

#### Conditions:

Cancer

#### Keywords:

Immune checkpoint inhibitor, Cancer, Disparities

### More Information

**Description:** This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Collecting samples of blood and saliva and health and treatment information from racially diverse patients receiving immune checkpoint inhibitor treatment over time may help doctors better understand health care disparities among all cancer patients.

**Study Contact:** Kristen Nelson - knelso65@fairview.org

**Principal Investigator:** Edward Greeno, M.D.

#### IRB

**Number:** MMCORC058

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.